The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

por Guan, J., Tucker, E. R., Wan, H., Chand, D., Danielson, L. S., Ruuth, K., El Wakil, A., Witek, B., Jamin, Y., Umapathy, G., Robinson, S. P., Johnson, T. W., Smeal, T., Martinsson, T., Chesler, L., Palmer, R. H., Hallberg, B.
Publicado 2016

SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma

por Carreno, G, Boult, J K R, Apps, J, Gonzalez-Meljem, J M, Haston, S, Guiho, R, Stache, C, Danielson, L S, Koers, A, Smith, L M, Virasami, A, Panousopoulos, L, Buchfelder, M, Jacques, T S, Chesler, L, Robinson, S P, Martinez-Barbera, J P
Publicado 2019